ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

Data Conference

More Like This

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting

ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference

ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

PR Newswire associated0

Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs

CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference